Alx Oncology Holdings Stock Performance
| ALXO Stock | USD 1.05 0.02 1.87% |
The firm shows a Beta (market volatility) of -0.74, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Alx Oncology are expected to decrease at a much lower rate. During the bear market, Alx Oncology is likely to outperform the market. At this point, Alx Oncology Holdings has a negative expected return of -0.32%. Please make sure to confirm Alx Oncology's potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Alx Oncology Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Alx Oncology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Acquisition by Jason Lettmann of 200000 shares of Alx Oncology at 1.66 subject to Rule 16b-3 | 12/02/2024 |
2 | ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 | 12/12/2024 |
3 | Disposition of 10796 shares by Jaume Pons of Alx Oncology at 1.5802 subject to Rule 16b-3 | 12/30/2024 |
4 | Disposition of 2221 shares by Shelly Pinto of Alx Oncology at 1.8 subject to Rule 16b-3 | 01/06/2025 |
5 | Is ALX Oncology Holdings Outperforming Other Medical Stocks This Year | 01/07/2025 |
6 | ALX Oncology Holdings Inc. Short Interest Update - MarketBeat | 01/17/2025 |
7 | ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 ... | 01/21/2025 |
8 | ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara K... | 01/22/2025 |
9 | ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating ... | 01/23/2025 |
10 | Disposition of 1617 shares by Randolph Sophia of Alx Oncology at 11.0704 subject to Rule 16b-3 | 02/06/2025 |
11 | ALX Oncology to Host Virtual RD Day on March 5, 2025 | 02/18/2025 |
12 | Disposition of 2159 shares by Jason Lettmann of Alx Oncology at 1.1502 subject to Rule 16b-3 | 02/19/2025 |
13 | Alx oncology ceo Jason Lettmann sells shares for 2,483 - Investing.com | 02/21/2025 |
| Begin Period Cash Flow | 48.9 M |
Alx |
Alx Oncology Relative Risk vs. Return Landscape
If you would invest 148.00 in Alx Oncology Holdings on November 28, 2024 and sell it today you would lose (43.00) from holding Alx Oncology Holdings or give up 29.05% of portfolio value over 90 days. Alx Oncology Holdings is currently does not generate positive expected returns and assumes 7.412% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Alx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alx Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alx Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alx Oncology Holdings, and traders can use it to determine the average amount a Alx Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0436
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALXO |
Estimated Market Risk
| 7.41 actual daily | 66 66% of assets are less volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alx Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alx Oncology by adding Alx Oncology to a well-diversified portfolio.
Alx Oncology Fundamentals Growth
Alx Stock prices reflect investors' perceptions of the future prospects and financial health of Alx Oncology, and Alx Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alx Stock performance.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (82.3 M) | ||||
| Shares Outstanding | 52.74 M | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 5,906 X | ||||
| Gross Profit | 107 K | ||||
| EBITDA | (158.4 M) | ||||
| Net Income | (160.81 M) | ||||
| Cash And Equivalents | 313.37 M | ||||
| Cash Per Share | 7.69 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.23 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (130.36 M) | ||||
| Earnings Per Share | (2.97) X | ||||
| Market Capitalization | 55.38 M | ||||
| Total Asset | 242.55 M | ||||
| Retained Earnings | (486.27 M) | ||||
| Working Capital | 152.66 M | ||||
About Alx Oncology Performance
By examining Alx Oncology's fundamental ratios, stakeholders can obtain critical insights into Alx Oncology's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alx Oncology is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -4 K | -4.2 K | |
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.97) | (0.93) |
Things to note about Alx Oncology Holdings performance evaluation
Checking the ongoing alerts about Alx Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alx Oncology Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alx Oncology generated a negative expected return over the last 90 days | |
| Alx Oncology has high historical volatility and very poor performance | |
| Alx Oncology has some characteristics of a very speculative penny stock | |
| Alx Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (160.81 M) with profit before overhead, payroll, taxes, and interest of 107 K. | |
| Alx Oncology Holdings currently holds about 313.37 M in cash with (130.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Alx Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Alx oncology ceo Jason Lettmann sells shares for 2,483 - Investing.com |
- Analyzing Alx Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alx Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Alx Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alx Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alx Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alx Oncology's stock. These opinions can provide insight into Alx Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.